Open the bid on the go! The third batch of volume procurement, 8 pictures of all-round analysis.

After the "4 plus 7", "4 plus 7" expansion and the second batch of national volume procurement in-depth exploration, operating experience is increasingly rich, with volume procurement has entered the normal, institutionalized and standardized stage.
The third batch of volume procurement is a sign of the beginning of normalization, with the vast number of patients and medical staff to the selection of varieties of increasing recognition, as well as the number of varieties included in the collection and coverage of the expansion, the volume of the "4 plus 7" 1.64 billion pieces / grain / bag / branch surged to the third batch of 2005 million pieces / grain / bag / branch (Figure 1), increased more than 11 times.
in the face of such a huge market temptation and the determination of the authorities to take full account of, as well as the balance left to cause the embarrassment of the unseeded varieties, the relevant enterprises will be actively involved, so the auction will remain extremely fierce.
Procurement volume with the increasing volume, its corresponding procurement volume also increased accordingly, from the "4 plus 7" of 1.9 billion yuan, "4 plus 7" of 3.5 billion yuan, the second batch of 8.8 billion yuan, has been increased to the third batch of collection of 22.65 billion yuan, compared with the initial "4 plus 7" also increased more than 11 times (Figure 2).
if the impact of the "4 plus 7" as a pilot on pharmaceutical companies is limited to the spirit, starting from the third batch, volume procurement will become an unavoidable mainstream event in the pharmaceutical industry.
2 varieties analysis the third batch of volume procurement involving a total of 56 varieties, 81 specifications, the total amount of up to 200.05 billion pieces / grain / bag / branch.
Among them, the largest amount is metformin oral regular release dosage form, up to 4.66 billion tablets, accounting for 23.3% of the total report; The total number of reports of omeprazole and python is as high as 10.58 billion tablets, accounting for more than half of the total number of reports (Figure 3), these varieties will also become the main object of fierce competition among pharmaceutical companies, especially metformin oral regular release agent type, there are as many as 28 enterprises with declared qualifications, and at most only 8 can be selected, the other 20 must be out, the intensity of competition can be imagined.
, the larger the purchase volume and the purchase amount will stimulate the degree of competition of enterprises, the third batch of total procurement volume of 22.65 billion yuan.
Among them, the highest purchase amount was moxiza star sodium chloride injection, up to 1.76 billion yuan, accounting for 7.8% of the total procurement volume;
In addition, the first seven varieties (Moxixacin, Tigrello, metformin oral reissue, 5mg of metformin, methylcobalamin, amino glucose, pivastatin) accounted for 39.5 per cent of total procurement, totalling 8.94 billion yuan (Figure 4).
3 provinces, there are great differences between different regions, in addition to the large differences in the amount reported and purchased between varieties.
of the country's 31 provinces, Guangdong Province was the largest, accounting for 9.7% of the total, with 1,944 million pieces/bags/pieces/bags/branch; accounted for 1 per cent, mainly due to the fact that its total population also accounted for only 2.5 per cent of the country's population, while the top five provinces (Guangdong, Zhejiang, Shandong, Jiangsu and Henan) accounted for 42 per cent of the country's total, amounting to 8.4 billion tablets/particles/bags/pieces/pieces(Figure 5).
Guangdong's largest reported volume, and some of its varieties of the large amount of the reported, such as Guangdong acid West that non-piece of the volume accounted for nearly 70% of the national report.
Although the collection of the highest effective declared price is not low, and the continuation of the second batch of "'unit comparable price' of 0.1000 yuan" can be selected to prevent the spread of low prices is the atmosphere, but based on the "first shun enterprise priority in the supply of Regional selection of 1 region" provisions, such as Guangdong, such as the super-large number of provinces still bring special temptation to enterprises, enterprises are not only satisfied with the winning bid, but try to use the lowest price to fight the "supply area to choose a region" priority, so as to obtain the largest number of provinces sales rights.
Previously in the second batch of 100 selected varieties, the price war is also very fierce, there are 30 varieties of the minimum specification price of less than 0.1 yuan, of which 17 minimum specification price is less than 6 cents (Figure 6).
The largest procurement volume is still in Guangdong Province, with a total of 2,594 million yuan, accounting for 11.46 percent of the country;The smallest is Qinghai Province, which accounts for only 46.17 million yuan, accounting for 2 percent of the country's total; and the top six provinces (Guangdong, Zhejiang, Jiangsu, Shanghai, Shandong and Beijing) account for just half of the country, amounting to 11.37 billion yuan (Figure 7).
4 first three reductions in price reduction is not the only measure of the effectiveness of strip procurement, but it is the most intuitive indicator, in addition to the average price reduction range, the largest decline of a single variety also attracted people's attention.
review of the decline in the first three national volume procurement, but also for the forecast of the decline of this collection to provide a reference.
the first three harvests, the average decline was basically maintained at a little more than 50%, the highest decline of a single species is more than 90%, the lowest decline of about 10%.
For example, the average decline of "4 plus 7" was 52%, the largest decrease was in the fumarate novovewaxel dipropide tablets, as high as 96.25%, the smallest decrease was 6.85 percent of the montite dispersion;
of the new medical reform has become a breakthrough, in the face of the normalization of the volume of procurement and the trend of full coverage, pharmaceutical companies can not avoid, only positive response is the best policy.
, stay at the sales level to deal with the impending poor, enterprises should be from the variety of projects, enterprise strategy and other more front-end and more macro-level transformation and upgrading is the best policy.
the third batch of volume purchases made on August 20th is the most urgent task.
.